Skip to main content

Advertisement

Log in

Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27kip1 levels

  • Original Paper
  • Published:
Oncogene Submit manuscript

Abstract

In recent years, increasing evidence indicated the importance of a deregulated c-myc gene in the melanoma pathogenesis. We have previously demonstrated that treatment of melanoma cells with c-myc antisense oligodeoxynucleotides can inhibit cell proliferation and activate apoptosis. To gain insight into the mechanisms activated by Myc down-regulation, we have now developed an experimental model that allows modulating Myc protein expression in melanoma cells. This was achieved by originating stable melanoma cell clones expressing ecdysone-inducible c-myc antisense RNA. We show that the induction of c-myc antisense RNA in M14 melanoma cells leads to an inhibition of cell proliferation characterized by accumulation of cells in the G1 phase of the cell cycle (up to 80%) and activation of apoptosis (50%). These data are associated with an increase of p27kip1 levels and a significant reduction of the cdk2-associated kinase activity. In addition, we show that an ectopic overexpression of p27kip1 in this experimental model can enhance the apoptotic rate. Our results indicate that down-regulation of Myc protein induces a G1 arrest and activates apoptosis by increasing p27kip1 content in melanoma cells, that are known to be defective for the p16-cyclinD/cdk4-pRb G1 checkpoint. This is particularly relevant for identifying new therapeutic strategies based on the re-establishment of the apoptotic pathways in cancer cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  • Bartkova J, Lukas J, Guldberg P, Alsner J, Kirkin AF, Zeuthen J, Bartek J . 1996 Cancer Res. 56: 5475–5483

  • Burgess TL, Fisher EF, Ross SL, Bready JV, Qian YX, Bayewitch LA, Cohen AM, Herrera CJ, Hu SS, Kramer TB . 1995 Proc. Natl. Acad. Sci. USA 92: 4051–4055

  • Castellano M, Parmiani G . 1999 Melanoma Res. 9: 421–432

  • Citro G, D'Agnano I, Leonetti C, Perini R, Bucci B, Zon G, Calabretta B, Zupi G . 1998 Cancer Res. 58: 283–289

  • Crooke ST . 1996 Antisense Nucleic Acid Drug Dev. 6: 145–147

  • D'Agnano I, Antonelli A, Bucci B, Marcucci L, Petrinelli P, Ambra R, Zupi G, Elli R . 1998 Environ. Mol. Mutagen. 32: 56–63

  • Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ . 1994 Oncogene 9: 3635–3645

  • Dang CV . 1999 Mol. Cell Biol. 19: 1–11

  • Evan G, Littlewood T . 1998 Science 281: 1317–1322

  • Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC . 1992 Cell 69: 119–128

  • Ezhevsky SA, Toyoshima H, Hunter T, Scott DW . 1996 Mol. Biol. Cell 7: 553–564

  • Fischer G, Kent SC, Joseph L, Green DR, Scott DW . 1994 J. Exp. Med. 179: 221–228

  • Hanson KD, Shichiri M, Follansbee MR, Sedivy JM . 1994 Mol. Cell Biol. 14: 5748–5755

  • Hoang AT, Cohen KJ, Barrett JF, Bergstrom DA, Dang CV . 1994 Proc. Natl. Acad. Sci. USA 91: 6875–6879

  • Jansen-Durr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, Wessbecher J, Draetta G, Eilers M . 1993 Proc. Natl. Acad. Sci. USA 90: 3685–3689

  • Kalejta RF, Shenk T, Beavis AJ . 1997 Cytometry 29: 286–291

  • Katayose Y, Kim M, Rakkar AN, Li Z, Cowan KH, Seth P . 1997 Cancer Res. 57: 5441–5445

  • Kimura S, Maekawa T, Hirakawa K, Murakami A, Abe T . 1995 Cancer Res. 55: 1379–1384

  • Krieg AM, Stein CA . 1995 Antisense Res. Dev. 5: 241

  • Leone G, DeGregori J, Sears R, Jakoi L, Nevins JR . 1997 Nature 387: 422–426

  • Leonetti C, D'Agnano I, Lozupone F, Valentini A, Geiser T, Zon G, Calabretta B, Citro GC, Zupi G . 1996 J. Natl. Cancer Inst. 88: 419–429

  • Lesnikowski ZJ, Jaworska M, Stec WJ . 1990 Nucleic Acids Res. 18: 2109–2115

  • Maelandsmo GM, Florenes VA, Hovig E, Oyjord T, Engebraaten O, Holm R, Borresen AL, Fodstad O . 1996 Br. J. Cancer 73: 909–916

  • Mateyak MK, Obaya AJ, Sedivy JM . 1999 Mol. Cell Biol. 19: 4672–4683

  • O'Hagan RC, Ohh M, David G, de Alboran IM, Alt FW, Kaelin Jr WG, DePinho RA . 2000 Genes Dev. 14: 2185–2191

  • Obaya AJ, Mateyak MK, Sedivy JM . 1999 Oncogene 18: 2934–2941

  • Perez-Roger I, Solomon DL, Sewing A, Land H . 1997 Oncogene 14: 2373–2381

  • Ross DA, Wilson GD . 1998 Br. J. Surg. 85: 46–51

  • Ryan KM, Birnie GD . 1996 Biochem. J. 314: 713–721

  • Schlagbauer-Wadl H, Griffioen M, van Elsas A, Schrier PI, Pustelnik T, Eichler HG, Wolff K, Pehamberger H, Jansen B . 1999 J. Invest. Dermatol. 112: 332–336

  • Schmidt EV . 1999 Oncogene 18: 2988–2996

  • Schraml P, Kononen J, Bubendorf L, Moch H, Bissig H, Nocito A, Mihatsch MJ, Kallioniemi OP, Sauter G . 1999 Clin. Cancer Res. 5: 1966–1975

  • Sheaff RJ, Groudine M, Gordon M, Roberts JM, Clurman BE . 1997 Genes Dev. 11: 1464–1478

  • Shi Y, Glynn JM, Guilbert LJ, Cotter TG, Bissonnette RP, Green DR . 1992 Science 257: 212–214

  • Skorski T, Nieborowska-Skorska M, Campbell K, Iozzo RV, Zon G, Darzynkiewicz Z, Calabretta B . 1995 J. Exp. Med. 182: 1645–1653

  • Stein CA . 1996 J. Natl. Cancer Inst. 88: 391–393

  • Stein CA . 1998 Antisense Nucleic Acid Drug Dev. 8: 129–132

  • Van den Heuvel S, Harlow E . 1993 Science 262: 2050–2054

  • van Waardenburg RC, Meijer C, Burger H, Nooter K, de Vries EG, Mulder NH, De Jong S . 1997 Int. J. Cancer 73: 544–550

  • Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B . 1996 EMBO J. 15: 6595–6604

  • Vlach J, Hennecke S, Amati B . 1997 EMBO J. 16: 5334–5344

  • Wang X, Gorospe M, Huang Y, Holbrook NJ . 1997 Oncogene 15: 2991–2997

  • Wu M, Bellas RE, Shen J, Yang W, Sonenshein GE . 1999 J. Immunol. 163: 6530–6535

Download references

Acknowledgements

We thank Maurizia Caruso for critically reading the manuscript; and Alessandra Rinaldi for technical assistance. This work was supported by grants from CNR, Target Project on Biotechnology (to I D'Agnano) and Progetto Strategico ‘Oncologia’ MURST-CNR (to A Felsani).

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

D'Agnano, I., Valentini, A., Fornari, C. et al. Myc down-regulation induces apoptosis in M14 melanoma cells by increasing p27kip1 levels. Oncogene 20, 2814–2825 (2001). https://doi.org/10.1038/sj.onc.1204392

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1204392

  • Springer Nature Limited

Keywords

This article is cited by

Navigation